DLG1 and breast cancer: However, the slightness of changes in relocation suggests that HPV16 E6 does not markedly affect localization of DLG1, and therefore the phenotype could be a result of other, unknown, processes during cancer progression, such as the acquisition of certain mutations, like G338R, I348V, G338R/I348V, and L329R/G330R in the DLG1 PDZ-2 domain in both HPV-negative and HPV-positive tumors during the process of oncogenesis, as has been seen in breast cancer.